NousCom CEO Outlines Cancer Vaccine Strategy
Executive Summary
NousCom CEO and co-founder Alfredo Nicosia speaks to Scrip senior editor Lucie Ellis during BIO-Europe, a partnering meeting held in berlin Nov. 6-8, about the company's recent series B financing.
You may also be interested in...
Inivata's John Beeler On The Future Of Liquid Biopsies
John Beeler, vice-president of corporate and business development at Inivata, speaks to Scrip's Lucie Ellis about how the company's technology is aligned with the current genomic medicine revolution facing the pharmaceutical industry.
NousCom Raises €42m For Novel Cancer Vaccines
European biotech NousCom is making ready two multi-neoantigen containing vaccines that with a new round of VC funding should enter clinical studies in 2018, and that it hopes to combine with checkpoint inhibitors.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.